Kewaunee Scientific Corporation (KEQU) Income Statement
KEQU FY2026 at a glance
Fiscal year ended April 30, 2026 · U.S. dollarsKEQU revenue and net income
Where KEQU's revenue goes
FY2026Each bar shows an amount and its share of revenue. KEQU kept 3.4% of revenue as net income.
KEQU profit margins
KEQU growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +17.3% | +8.7% | +13.8% | +8.2% |
| Gross profit | +16.8% | +31.2% | +27.4% | +13.0% |
| Operating income | −5.9% | +66.3% | — | +11.4% |
| Net income | −15.7% | +92.0% | — | +9.7% |
| EPS (diluted) | −30.7% | +140.1% | — | +8.9% |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
KEQU quarterly EPS vs estimates
Kewaunee Scientific beat the analyst EPS estimate in 3 of the last 3 quarters. Next report: December 9, 2026.
KEQU income statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $282.0M | $240.5M | $203.8M | $219.5M | $168.9M | $147.5M | $147.5M | $146.6M | $158.1M | $138.6M |
| Cost of revenue | $201.6M | $171.6M | $151.7M | $183.9M | $144.7M | $123.5M | $124.1M | $121.2M | $126.0M | $112.0M |
| Gross profit | $80.4M | $68.9M | $52.1M | $35.6M | $24.2M | $24.0M | $23.4M | $25.3M | $32.0M | $26.6M |
| Research & development | $898,000 | — | $920,000 | $1.0M | $990,000 | $1.4M | $1.8M | $1.6M | $1.5M | $1.2M |
| Sales, general & admin | $63.7M | $51.1M | $37.6M | $29.7M | $26.6M | $26.3M | $25.9M | $23.0M | $22.9M | $20.1M |
| Total operating expenses | $63.7M | $51.1M | $33.8M | $30.2M | $26.8M | $25.3M | $25.8M | $23.2M | $22.9M | $20.1M |
| Operating income | $16.7M | $17.8M | $18.3M | $3.6M | −$2.6M | −$1.3M | −$2.3M | $2.1M | $9.1M | $6.5M |
| Interest income | — | — | — | — | — | — | $493,000 | $367,000 | $299,000 | $292,000 |
| Interest expense | $3.9M | $3.2M | $1.8M | $1.7M | $632,000 | $389,000 | $493,000 | $367,000 | $299,000 | $292,000 |
| Income before taxes | $13.7M | $14.8M | $13.1M | $4.5M | −$2.5M | −$2.6M | −$2.9M | $2.1M | $9.5M | $6.7M |
| Income taxes | $3.3M | $3.2M | −$5.9M | $3.1M | $3.5M | $990,000 | $1.8M | $446,000 | $4.1M | $2.1M |
| Net income | $9.6M | $11.4M | $18.8M | $1.4M | −$6.0M | −$3.6M | −$4.6M | $1.5M | $5.2M | $4.5M |
| EBITDA | $23.9M | $22.8M | $18.0M | $8.2M | $916,000 | $459,000 | $281,000 | $4.7M | $12.0M | $9.2M |
| EPS (diluted) | $3.32 | $4.79 | $6.35 | $0.24 | −$2.20 | −$1.51 | −$1.71 | $0.85 | $2.27 | $1.66 |
| Gross margin | 28.5% | 28.6% | 25.5% | 16.2% | 14.3% | 16.3% | 15.9% | 17.3% | 20.3% | 19.2% |
| Operating margin | 5.9% | 7.4% | 9.0% | 1.7% | −1.5% | −0.9% | −1.6% | 1.4% | 5.7% | 4.7% |
| Net margin | 3.4% | 4.7% | 9.2% | 0.6% | −3.6% | −2.4% | −3.1% | 1.0% | 3.3% | 3.3% |
| Jul '26 | Apr '26 | Jan '26 | Oct '25 | Jul '25 | Apr '25 | Jan '25 | Oct '24 | Jul '24 | Apr '24 | Jan '24 | Oct '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $66.3M | $71.4M | $69.4M | $70.1M | $71.1M | $77.1M | $67.2M | $47.8M | $48.4M | $56.7M | $46.8M | $50.4M |
| Cost of revenue | $46.7M | $50.2M | $50.9M | $50.4M | $50.2M | $53.1M | $48.8M | $33.8M | $35.9M | $42.1M | $34.7M | $37.0M |
| Gross profit | $19.6M | $21.2M | $18.5M | $19.7M | $20.9M | $24.0M | $18.4M | $14.0M | $12.5M | $14.6M | $12.0M | $13.5M |
| Research & development | — | $898,000 | — | — | — | $919,000 | — | — | — | $920,000 | — | — |
| Sales, general & admin | — | $14.5M | — | — | — | $14.6M | — | $0 | — | $4.1M | $8.2M | $40,000 |
| Total operating expenses | $16.5M | $16.0M | $16.0M | $15.6M | $16.1M | $15.5M | $16.1M | $9.5M | $9.9M | $9.1M | $8.2M | $8.4M |
| Operating income | $3.2M | $5.2M | $2.6M | $4.1M | $4.8M | $8.5M | $2.2M | $4.4M | $2.6M | $5.6M | $3.8M | $5.1M |
| Interest expense | $626,000 | $631,000 | $1.1M | $1.1M | $1.1M | $1.2M | $1.1M | $442,000 | $472,000 | $586,000 | $411,000 | $372,000 |
| Income before taxes | $2.6M | $4.8M | $1.6M | $3.5M | $3.9M | $7.1M | $1.3M | $3.9M | $2.4M | $1.3M | $3.5M | $4.8M |
| Income taxes | $717,000 | $1.1M | $528,000 | $915,000 | $761,000 | $2.2M | −$108,000 | $916,000 | $192,000 | −$9.8M | $982,000 | $2.0M |
| Net income | $1.7M | $3.4M | $692,000 | $2.4M | $3.1M | $4.8M | $1.4M | $3.0M | $2.2M | $11.0M | $2.5M | $2.7M |
| EBITDA | $4.7M | $6.9M | $4.3M | $6.1M | $6.5M | $9.9M | $4.0M | $5.2M | $3.7M | $2.3M | $4.6M | $5.8M |
| EPS (diluted) | $0.58 | $1.14 | $0.23 | $0.91 | $1.04 | $1.95 | $1.09 | $1.01 | $0.74 | $3.71 | $0.85 | $0.93 |
| Gross margin | 29.6% | 29.8% | 26.7% | 28.1% | 29.4% | 31.2% | 27.4% | 29.2% | 25.8% | 25.8% | 25.7% | 26.7% |
| Operating margin | 4.8% | 7.3% | 3.7% | 5.9% | 6.8% | 11.0% | 3.3% | 9.3% | 5.3% | 9.8% | 8.1% | 10.1% |
| Net margin | 2.6% | 4.7% | 1.0% | 3.5% | 4.3% | 6.3% | 2.0% | 6.3% | 4.5% | 19.4% | 5.4% | 5.4% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in KEQU's financial statements (latest annual report filed June 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
KEQU financial results
In fiscal year 2026 (ended April 30, 2026), Kewaunee Scientific reported revenue of $282.0 million, up 17.3% from the year before. It had net income of $9.6 million (down 15.7%), a net profit margin of 3.4%. Diluted earnings per share came to $3.32. Over five years revenue grew at an average rate of 13.8% a year.
See the KEQU stock overview for the latest quote and news, or the KEQU chart for price history and technical indicators.
KEQU income statement FAQ
What is Kewaunee Scientific's annual revenue?
Kewaunee Scientific reported total revenue of $282.0 million for fiscal year 2026, which ended on April 30, 2026. That was up 17.3% from $240.5 million the previous year.
Is Kewaunee Scientific profitable?
Yes. Kewaunee Scientific reported net income of $9.6 million in fiscal 2026, a net profit margin of 3.4%; its operating margin was 5.9%.
What is Kewaunee Scientific's gross margin?
Kewaunee Scientific's gross margin was 28.5% in fiscal 2026: for every $100 of revenue, Kewaunee Scientific kept $29 after the direct cost of its products and services.
How much does Kewaunee Scientific spend on research and development?
Kewaunee Scientific spent $0.9 million on research and development in fiscal 2026, 0.3% of revenue.
How fast is Kewaunee Scientific growing?
Revenue grew 13.8% a year on average over the last five fiscal years, from $147.5 million to $282.0 million.
What are Kewaunee Scientific's earnings per share?
Kewaunee Scientific earned $3.32 per diluted share in fiscal 2026, compared with $4.79 a year earlier.
When will Kewaunee Scientific report its next earnings?
Kewaunee Scientific is expected to report results for the quarter ending October 31, 2026 on December 9, 2026.
When does Kewaunee Scientific's fiscal year end?
Kewaunee Scientific's fiscal year ends in April. The latest annual report covers the year ended April 30, 2026 and was filed on June 26, 2026.